Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
WARNING
NOT FOR INTRATHECAL USE
Optiray (ioversol injection) formulations are sterile, nonpyrogenic, aqueous solutions intended for intravascular administration as diagnostic radiopaque media. Ioversol is designated chemically as N,N'-Bis (2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl) glycolamido] -2,4,6-triiodoisophthalamide and has the following structural formula:
 |
The molecular weight of ioversol is 807.11 and the organically bound iodine content is 47.2%. Ioversol is nonionic and does not dissociate in solution.
Each milliliter of Optiray 350 (ioversol injection 74%) contains 741 mg of ioversol with 3.6 mg of tromethamine as a buffer and 0.2 mg of edetate calcium disodium as a stabilizer. Optiray 350 provides 35% (350 mg/mL) organically bound iodine.
Each milliliter of Optiray 320 (ioversol injection 68%) contains 678 mg of ioversol with 3.6 mg of tromethamine as a buffer and 0.2 mg of edetate calcium disodium as a stabilizer. Optiray 320 provides 32% (320 mg/mL) organically bound iodine.
Each milliliter of Optiray 300 (ioversol injection 64%) contains 636 mg of ioversol with 3.6 mg of tromethamine as a buffer and 0.2 mg of edetate calcium disodium as a stabilizer. Optiray 300 provides 30% (300 mg/mL) organically bound iodine.
Each milliliter of Optiray 240 (ioversol injection 51%) contains 509 mg of ioversol with 3.6 mg of tromethamine as a buffer and 0.2 mg of edetate calcium disodium as a stabilizer. Optiray 240 provides 24% (240 mg/mL) organically bound iodine.
The pH of the Optiray formulations has been adjusted to 6.0 to 7.4 with hydrochloric acid or sodium hydroxide. All solutions are sterilized by autoclaving and contain no preservatives. Unused portions should be discarded. Optiray solutions are sensitive to light and therefore should be protected from exposure.
Some physical and chemical properties of these formulations are listed below:
| Optiray 240 | Optiray 300 | Optiray 320 | Optiray 350 | |
| Ioversol content(mg/mL) | 509 | 636 | 678 | 741 |
| Iodine content(mg I/mL) | 240 | 300 | 320 | 350 |
| Osmolality (mOsm/kg water) | 502 | 651 | 702 | 792 |
| Viscosity (cps) | ||||
| at 25°C | 4.6 | 8.2 | 9.9 | 14.3 |
| at 37°C | 3.0 | 5.5 | 5.8 | 9.0 |
| Specific Gravity at 37°C | 1.281 | 1.352 | 1.371 | 1.405 |
The Optiray formulations are clear, colorless to pale yellow solutions containing no undissolved solids. Crystallization does not occur at room temperature. The products are supplied in containers from which the air has been displaced by nitrogen. Optiray solutions have osmolalities 1.8 to 2.8 times that of plasma (285 mOsm/kg water) as shown in the above table and are hypertonic under conditions of use.
OPTIRAY is indicated for:
Use OPTIRAY 300 or OPTIRAY 320. The recommended dose for visualization of cerebral arteries is shown below (may repeat as necessary):
| Diagnostic area | Dose | Maximum Cumulative Dose |
| carotid or vertebral arteries | 2 to 12 mL | 200 mL |
| aortic arch injection (four vessel study) |
20 to 50 mL | 200 mL |
Use OPTIRAY 300, OPTIRAY 320 or OPTIRAY 350. The recommended dose for visualization of peripheral arteries is shown below (may repeat as necessary):
| Diagnostic area | Dose | Maximum Cumulative Dose |
| aorta-iliac runoff | 60 mL (range 20 to 90 mL) | 250 mL |
| common iliac, femoral | 40 mL (range 10 to 50 mL) | 250 mL |
| subclavian, brachial | 20 mL (range 15 to 30 mL) | 250 mL |
Use OPTIRAY 320. The recommended dose for visualization for the aorta and visceral arteries is shown below (may repeat as necessary):
| Diagnostic area | Dose | Maximum Cumulative Dose |
| Aorta | 45 mL (range 10 to 80 mL) | 250 mL |
| Celiac | 45 mL (range 12 to 60 mL) | 250 mL |
| superior mesenteric | 45 mL (range 15 to 60 mL) | 250 mL |
| renal or inferior mesenteric | 9 mL (range 6 to 15 mL) | 250 mL |
Use OPTIRAY 320 or OPTIRAY 350. The recommended dose for visualization of the coronary arteries and left ventricle is shown below (may repeat as necessary):
| Diagnostic area | Dose | Maximum Cumulative Dose |
| left coronary | 8 mL (range 2 to 10 mL) | 250 mL |
| right coronary | 6 mL (range 1 to 10 mL) | 250 mL |
| left ventricle | 40 mL (range 30 to 50 mL) | 250 mL |
Use OPTIRAY 300, OPTIRAY 320 or OPTIRAY 350 for head and body imaging.
The recommended dosing is shown below:
| Infusion | |
| OPTIRAY 300 | 50 to 150 mL |
| OPTIRAY 320 | 50 to 150 mL |
| OPTIRAY 350 | 50 to 150 mL |
OPTIRAY may be administered by bolus injection, by rapid infusion, or by a combination of both. The recommended dosing is shown below:
| Bolus Injection | Infusion | |
| OPTIRAY 300 | 25 to 75 mL | 50 to 150 mL |
| OPTIRAY 320 | 25 to 75 mL | 50 to 150 mL |
| OPTIRAY 350 | 25 to 75 mL | 50 to 150 mL |
Use OPTIRAY 300, OPTIRAY 320 or OPTIRAY 350. The recommended dose is 50 to 100 mL per extremity; with a maximum cumulative dose of 250 mL.
Use OPTIRAY 350, OPTIRAY 320, or OPTIRAY 300. The recommended dose is shown below:
| Usual Dose | High Dose Urography | Maximum Dose | |
| OPTIRAY 300 | 50 to 75 mL | 1.6 mL/kg | 150 mL |
| OPTIRAY 320 | 50 to 75 mL | 1.5 to 2 mL/kg | 150 mL |
| OPTIRAY 350 | 50 to 75 mL | 1.4 mL/kg | 140 mL |
Use OPTIRAY 350. The recommended dose range per injection is 30 to 50 mL; may repeat as necessary with a maximum cumulative dose of 250mL.
Injection rates will vary depending on the site of catheter placement and vessel size.
Use OPTIRAY 350 or OPTIRAY 320. The recommended single ventricular dose is 1.25 mL/kg (range 1 mL/kg to 1.5 mL/kg). The maximum cumulative dose is 5 mL/kg up to a maximum total volume of 250 mL.
Use OPTIRAY 320.
The recommended dose in pediatric patients is 1.5 mL/kg to 2 mL/kg (range 1 mL/kg to 3 mL/kg).
Use OPTIRAY 320. The recommended dose for pediatric patients is 1 mL/kg to 1.5 mL/kg (range 0.5 mL/kg to 3 mL/kg); with a maximum cumulative dose not exceeding 3 mL/kg.
Injection: clear, colorless to pale yellow solutions containing no undissolved solids, available in the following strengths and single-dose containers:
| Imaging Product | mg of ioversol per mL | mg of organically boundiodine per mL | Presentations | |||
| Vials | Bottles | Hand-held syringes | Power injector syringes | |||
| OPTIRAY 300 (Ioversol 64%) |
636 | 300 | No | Yes | Yes | Yes |
| OPTIRAY 320 (Ioversol 68%) |
678 | 320 | Yes | Yes | Yes | Yes |
| OPTIRAY 350 (Ioversol 74%) |
741 | 350 | No | Yes | Yes | Yes |
OPTIRAY is a clear, colorless to pale yellow, sterile, pyrogen-free, aqueous solution available in three strengths. The products are supplied in containers from which the air has been displaced by nitrogen. OPTIRAY is supplied in the following single-dose configurations:
| OPTIRAY 350 | NDC Number |
| Glass | |
| 25x50 mL bottles | 0019-1333-06 |
| 12x100 mL bottles | 0019-1333-11 |
| 12x150 mL bottles | 0019-1333-16 |
| 12x200 mL fill/250 mL bottles | 0019-1333-21 |
| Plastic | |
| 20x50 mL hand held syringes | 0019-1333-78 |
| 20x50 mL fill/125 mL power injector syringes | 0019-1333-52 |
| 20x75 mL fill/125 mL power injector syringes | 0019-1333-95 |
| 20x100 mL fill/125 mL power injector syringes | 0019-1333-90 |
| 20x125 mL power injector syringes | 0019-1333-87 |
| RFID-Tagged Syringes* | |
| 20x50 mL fill/125 mL power injector syringes | 0019-1333-55 |
| 20x100 mL fill/125 mL power injector syringes | 0019-1333-00 |
| 20x125 mL power injector syringes | 0019-1333-27 |
| *Radio Frequency Identification (RFID) Technology | |
| OPTIRAY 320 | NDC Number |
| Glass | |
| 25x20 mL vials | 0019-1323-02 |
| 25x30 mL vials | 0019-1323-04 |
| 25x50 mL bottles | 0019-1323-06 |
| 12x100 mL bottles | 0019-1323-11 |
| 12x150 mL bottles | 0019-1323-16 |
| 12x200 mL fill/250 mL bottles | 0019-1323-21 |
| Plastic | |
| 20x50 mL hand held syringes | 0019-1323-78 |
| 20x50 mL fill/125 mL power injector syringes | 0019-1323-52 |
| 20x75 mL fill/125 mL power injector syringes | 0019-1323-95 |
| 20x100 mL fill/125 mL power injector syringes | 0019-1323-90 |
| 20x125 mL power injector syringes | 0019-1323-87 |
| RFID-Tagged Syringes* | |
| 20x75 mL fill/125 mL power injector syringes | 0019-1323-85 |
| 20x100 mL fill/125 mL power injector syringes | 0019-1323-00 |
| 20x125 mL power injector syringes | 0019-1323-27 |
| *Radio Frequency Identification (RFID) Technology | |
| OPTIRAY 300 | NDC Number |
| Glass | |
| 25x50 mL bottles | 0019-1332-06 |
| 12x100 mL bottles | 0019-1332-11 |
| 12x150 mL bottles | 0019-1332-16 |
| 12x200 mL fill/250 mL bottles | 0019-1332-21 |
| Plastic | |
| 20x50 mL hand held syringes | 0019-1332-78 |
| 20x100 mL fill/125 mL power injector syringes | 0019-1332-90 |
| RFID-Tagged Syringes* | |
| 20x100 mL fill/125 mL power injector syringes | 0019-1332-00 |
| *Radio Frequency Identification (RFID) Technology | |
This information is for Ultraject™ syringes containing OPTIRAY that have been labeled with a Radio Frequency Identification (RFID) tag. When used with an RFID-enabled Optivantage™ injector, this tag allows for the exchange of product information such as lot number, expiration, concentration, and identification of the syringe as being “unused” prior to use and “used” after product administrations. Patient information is not used in any form with this RFID technology. OPTIRAY product quality is not influenced by the use of this RFID tag.
For the RFID Technology to function, the syringe must be used with an Optivantage Injector with RFID technology [see DOSAGE AND ADMINISTRATION]. Function of the RFID technology is not dependent on syringe orientation as it is placed in the injector. Instructions for use of injector are provided on the injector interface screen and operator’s manual.
If the RFID tag is damaged or otherwise non-functional, the injector will notify the user. Should this occur the OPTIRAY syringe with the non-functional RFID tag may still be used but no data will be transferred to the injector.
Regarding interference with medical devices, the RFID tag and injector system meet the IEC 60601-12 requirements for emission and immunity standards for medical devices. Follow all manufacturers’ guidelines and do not operate any part of the Optivantage Injector System and RFID-tagged syringes within 6 inches (15 cm) of a pacemaker and/or defibrillator.
Manufactured by: Liebel-Flarsheim Company LLC Raleigh, NC 27616. Revised Feb 2022.
The following clinically significant adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The following listing shows adverse reactions based upon clinical trials with OPTIRAY (ioversol) in 4,187 patients. Adverse reactions are listed by organ system according to clinical importance. More severe reactions are listed before others in a system regardless of incidence. The most common reaction is nausea, occurring at a rate of 1 percent.
Cardiac Disorders
Cardiac arrest, myocardial infarction, arrhythmia, atrioventricular block complete, atrioventricular block, nodal rhythm, bradycardia, angina pectoris, palpitations
Ear and Labyrinth Disorders
Vertigo, tinnitus
Eye Disorders
Vision blurred, periorbital edema, conjunctivitis
Gastrointestinal Disorders
Nausea, vomiting, abdominal pain, dysphagia, dry mouth
General Disorders and Administration Site Conditions
Chest pain, pain, injection site pain, injection site hematoma, extravasation, pyrexia, swelling, asthenia, malaise, fatigue, chills
Infections and Infestations
Rhinitis
Injury, Poisoning, and Procedural Complications
Heart injury, vascular pseudoaneurysm
Investigations
Electrocardiogram ST segment depression, blood pressure decreased
Metabolism and Nutrition Disorders
Acidosis
Musculoskeletal and Connective Tissue Disorders
Muscular weakness, muscle spasms, back pain
Nervous System Disorders
Cerebral infarction, aphasia, tremor, dizziness, presyncope, headache, paraesthesia, dysgeusia
Psychiatric Disorders
Hallucination, visual hallucination, disorientation, anxiety
Renal and Yrinary Disorders
Urinary retention, renal pain, polyuria
Respiratory, Thoracic, and Mediastinal Disorders
Laryngeal edema, hypoxia, pulmonary edema, dyspnea, hyperventilation, cough, sneezing, nasal congestion
Skin and Subcutaneous Tissue Disorders
Urticaria, rash, pruritus, swelling face, hyperhidrosis, erythema
Vascular Disorders
Hypertension, hypotension, arterial spasm, vasospasm, vasodilation, flushing
In clinical studies involving 311 patients for pediatric angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography; 6% of patients reported an adverse reaction, with the most common adverse reactions being nausea and fever. Adverse reactions reported were similar in quality and frequency to the adverse events reported by adults.
The following additional adverse drug reactions have been reported during post-approval use of OPTIRAY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure.
Cardiac disorders: coronary artery spasm, cyanosis, arrhythmia (ventricular fibrillation, tachycardia, extrasystole), ECG abnormal.
Endocrine disorders Hyperthyroidism, hypothyroidism.
Eye disorders: temporary blindness, conjunctivitis (including eye irritation, ocular hyperemia, watery eyes).
Gastrointestinal disorders: tongue edema, salivary hypersecretion.
General disorders and administration site conditions: injection site reactions including pain, hemorrhage, and necrosis especially after extravasation [see WARNINGS AND PRECAUTIONS], face edema, feeling hot.
Immune system disorders: hypersensitivity reactions including fatal anaphylactic shock.
Nervous system disorders: seizure, loss of consciousness, somnolence, hypoesthesia, dyskinesia, amnesia.
Respiratory disorders: Respiratory arrest, asthma, bronchospasm, laryngeal spasm and obstruction, throat irritation, dysphonia.
Skin and subcutaneous tissue disorders: Reactions range from mild (e.g. rash, erythema, pruritus, urticaria, and skin discoloration) to severe: [e.g. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN)], acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS).
Vascular Disorders: phlebitis, thrombosis.
In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents. Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute only after renal function is stable.
Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131) and decrease therapeutic efficacy in patients with carcinoma of the thyroid. The decrease in efficacy lasts for 6-8 weeks.
Renal toxicity has been reported in patients with liver impairment who were given oral cholecystographic agents followed by intravascular contrast agents. Administration of OPTIRAY should be postponed in patients who have recently received a cholecystographic contrast agent.
The results of protein bound iodine and radioactive iodine uptake studies, which depend on iodine estimation, will not accurately reflect thyroid function for up to 16 days following administration of iodinated contrast agent. However, thyroid function tests that do not depend on iodine estimations, e.g., T3 resin uptake and total or free thyroxine (T4) assays are not affected.
Included as part of the "PRECAUTIONS" Section
OPTIRAY is indicated for intravascular use only [see DOSAGE AND ADMINISTRATION]. Inadvertent intrathecal administration can cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema.
OPTIRAY can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock. Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock. Most severe reactions develop shortly after the start of the injection (e.g. within 1 to 3 minutes), but delayed reactions may occur. There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities. Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.
Obtain a history of allergy, hypersensitivity, or prior hypersensitivity reactions to iodinated contrast agents. Always have emergency resuscitation equipment and trained personnel available and monitor all patients for hypersensitivity reactions.
Acute kidney injury, including renal failure, may occur after OPTIRAY administration. Risk factors include: pre-existing renal impairment, dehydration, diabetes mellitus, congestive heart failure, advanced vascular disease, elderly age, concomitant use of nephrotoxic or diuretic medications, multiple myeloma / paraproteinaceous diseases, repetitive and/or large doses of an iodinated contrast agent. Use the lowest necessary dose of OPTIRAY in patients with renal impairment. Adequately hydrate patients prior to and following OPTIRAY administration. Do not use laxatives, diuretics, or preparatory dehydration prior to OPTIRAY administration.
OPTIRAY increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, severely impaired renal function, combined renal and hepatic disease, combined renal and cardiac disease, particularly when repetitive or large doses are administered.
Life-threatening or fatal cardiovascular reactions have occurred with the use of OPTIRAY, including cardiac arrest, hypotensive collapse, and shock. Most deaths occur within 10 minutes of injection; with cardiovascular disease as the main underlying factor. Cardiac decompensation, serious arrhythmias, and myocardial ischemia or infarction can occur during coronary arteriography and ventriculography.
Based upon literature reports, deaths from the administration of iodinated contrast agents range from 6.6 per 1 million (0.00066 percent) to 1 in 10,000 patients (0.01 percent). Use the lowest necessary dose of OPTIRAY in patients with congestive heart failure and always have emergency resuscitation equipment and trained personnel available. Monitor all patients for severe cardiovascular reactions.
Serious, fatal, thromboembolic events causing myocardial infarction and stroke can occur during angiographic procedures with OPTIRAY. During these procedures, increased thrombosis and activation of the complement system occurs. Risk factors for thromboembolic events include: length of procedure, catheter and syringe material, underlying disease state, and concomitant medications.
To minimize thromboembolic events use meticulous angiographic technique. Avoid blood remaining in contact with syringes containing OPTIRAY, which increases the risk of clotting. Avoid angiocardiography in patients with homocystinuria because of the risk of inducing thrombosis and embolism [see CLINICAL PHARMACOLOGY].
Extravasation can occur with OPTIRAY administration, particularly in patients with severe arterial or venous disease and can be associated with pain, hemorrhage and necrosis. Ensure intravascular placement of catheters prior to injection. Monitor patients for extravasation and advise patients to seek medical care for progression of symptoms.
OPTIRAY is contraindicated in patients with symptomatic hyperthyroidism [see CONTRAINDICATIONS]. Thyroid storm has occurred following the intravascular use of iodinated radiopaque agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule. Evaluate the risk in such patients before use of OPTIRAY.
Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression has been reported after both single exposure and multiple exposures to iodinated contrast media. Among patients 0 to 3 years of age exposed to iodinated contrast media, thyroid dysfunction has been reported in 1% to 15% depending on the age of the patient and the dose of the iodinated contrast agent.
Younger age, very low birth weight, prematurity, and the presence of other conditions, such as, admission to neonatal or pediatric intensive care units, and cardiac conditions are associated with an increased risk. Pediatric patients with cardiac conditions may be at the greatest risk given that they often require high doses of contrast during invasive cardiac procedures, such as catheterization and computed tomography (CT).
Pediatric patients 0 to 3 years of age warrant closer monitoring because an underactive thyroid during early life may be harmful for motor, hearing, and cognitive development and may require transient T4 replacement therapy. Evaluate thyroid function in all pediatric patients 0 to 3 years of age within 3 weeks following exposure to iodinated contrast media, especially in term and preterm neonates. If thyroid dysfunction is detected, treat and monitor thyroid function as clinically needed.
Hypertensive crisis has occurred after the use of iodinated radiopaque contrast agents in patient with pheochromocytoma. Closely monitor patients when administering OPTIRAY if pheochromocytoma or catecholamine-secreting paraganglioma is suspected. Inject the minimum amount of OPTIRAY necessary and have measures for treatment of hypertensive crisis readily available.
Iodinated contrast agents may promote sickling in individuals who are homozygous for sickle cell disease. Hydrate patients prior to and following OPTIRAY administration, use OPTIRAY only if the necessary imaging information cannot be obtained with alternative imaging modalities, and inject the minimum amount necessary.
Severe cutaneous adverse reactions (SCAR) may develop from 1 hour to several weeks after intravascular contrast agent administration. These reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS). Reaction severity may increase and time to onset may decrease with repeat administration of a contrast agent; prophylactic medications may not prevent or mitigate severe cutaneous adverse reactions. Avoid administering OPTIRAY to patients with a history of a severe cutaneous adverse reaction to OPTIRAY.
No long term animal studies have been performed to evaluate carcinogenic potential. Nonclinical studies show that ioversol is not mutagenic and does not affect fertility.
Postmarketing data with OPTIRAY use in pregnant women are insufficient to determine if there is a risk of drug-associated adverse developmental outcomes. Ioversol crosses the placenta and reaches fetal tissues in small amounts [see Data]. In animal reproduction studies, no adverse developmental effects were observed following daily intravenous administrations of ioversol to pregnant rats (from Gestation Day 7 to 17) and rabbits (Gestation Day 6 to 18) at doses 0.35 and 0.71 times, respectively, the maximum recommended human dose.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Human Data
Literature reports show that ioversol crosses the placenta and is visualized in the digestive tract of exposed infants after birth.
Animal Data
Developmental toxicity studies were conducted with ioversol given intravenously at doses of 0, 0.2, 0.8, and 3.2 g iodine/kg/day from Gestation Day 7 to 17 and 6 to 18, in rats and rabbits, respectively. No adverse effects on embryo-fetal development were observed in either species at the maximum dose tested (3.2 g iodine/kg/day). Maternal toxicity was observed in rabbits at 0.8 and 3.2 g iodine/kg/day.
There is no information about the presence of ioversol in human or animal milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. However, iodinated contrast agents are excreted unchanged in human milk in very low amounts with poor absorption from the gastrointestinal tract of the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for OPTIRAY and any potential adverse effects on the breastfed infant from OPTIRAY or from the underlying maternal condition.
Interruption of breastfeeding after exposure to iodinated contrast agents is not necessary because the potential exposure of the breastfed infant to iodine is small. However, a lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk for 8 hours (approximately 5 elimination half-lives) after OPTIRAY administration in order to minimize drug exposure to a breastfed infant.
Safety and effectiveness in pediatric patients have been established for the use of OPTIRAY 350 and OPTIRAY 320 in angiocardiography; and for OPTIRAY 320 in computed tomographic imaging of the head and body, and intravenous excretory urography. Use of OPTIRAY 350 and OPTIRAY 320 in these age groups is based on controlled clinical trials involving 159 patients for pediatric angiocardiography; computed tomographic imaging of the head and body, and intravenous excretory urography. In general, the types of adverse reactions reported are similar to those of adults [see ADVERSE REACTIONS].
Safety and effectiveness of OPTIRAY 300 has not been established in pediatric patients.
Pediatric patients at higher risk of experiencing adverse reactions to OPTIRAY include patients with: asthma, sensitivity to medication and/or allergens, congestive heart failure, serum creatinine greater than 1.5 mg/dL, or age less than 12 months.
Thyroid function tests indicative of thyroid dysfunction, characterized by hypothyroidism or transient thyroid suppression have been uncommonly reported following iodinated contrast media administration in pediatric patients, including term and preterm neonates;some patients were treated for hypothyroidism. Monitor pediatric patients 0 to 3 years of age closely, particularly those with one or more potential risk factors, for thyroid dysfunction [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].
Ioversol is nearly completely excreted as parent drug by the kidney, and the risk of adverse reactions to OPTIRAY may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, dose selection should be cautious usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
Ioversol is nearly completely excreted as parent drug by the kidney and renal impairment is expected to reduce the rate of elimination. Ioversol can be removed by dialysis.
The adverse effects of overdosage are life-threatening and affect mainly the pulmonary and cardiovascular system. Treatment of an overdosage is directed toward the support of all vital functions and prompt institution of symptomatic therapy.
Ioversol does not bind to plasma or serum protein and is, therefore, dialyzable.
Symptomatic hyperthyroidism.
Intravascular injection of ioversol opacifies vessels in the path of the flow of the contrast medium, permitting visualization of the internal structures until significant hemodilution occurs.
In imaging of the body, iodinated contrast agents diffuse from the vascular into the extravascular space. In normal brain with an intact blood-brain barrier, contrast does not diffuse into the extravascular space. In patients with a disrupted blood-brain barrier, contrast agent accumulates in the interstitial space in the region of disruption.
Following administration of OPTIRAY, the degree of enhancement is directly related to the iodine content in an administered dose. Peak iodine plasma levels occur immediately following rapid injection. The time to maximum contrast enhancement can vary, depending on the organ, from the time that peak blood iodine concentrations are reached to one hour after intravenous bolus administration. When a delay between peak blood iodine concentrations and peak contrast is present, it suggests that radiographic contrast enhancement is at least in part dependent on the accumulation of iodine-containing medium within the lesion and outside the blood pool.
For angiography, contrast enhancement is greatest immediately (15 seconds to 120 seconds) after rapid injection. Iodinated contrast agents may be visualized in the renal parenchyma within 30-60 seconds following rapid intravenous injection. Opacification of the calyces and pelves in patients with normal renal function becomes apparent within 1-3 minutes, with optimum contrast occurring within 515 minutes.
In 12 healthy volunteers (6 receiving 50 mL and 6 receiving 150 mL of OPTIRAY 320), elimination half-life was 1.5 hours for both doses.
In an in vitro human plasma study, ioversol did not bind to protein. The volume of distribution in adults was 0.26 L/kg body weight, consistent with distribution to the extracellular space.
Metabolism
Ioversol does not undergo significant metabolism, deiodination or biotransformation.
Excretion
Greater than 95% of the administered dose was excreted in urine within the first 24 hours, with the peak urine concentration occurring in the first two hours after administration.
Animal studies indicate that ioversol does not cross the blood-brain barrier.
Advise the patient concerning the risk of hypersensitivity reactions that can occur both during and after OPTIRAY administration. Advise the patient to report any signs or symptoms of hypersensitivity reactions during the procedure and to seek medical attention for signs or symptoms experienced after discharge [see WARNINGS AND PRECAUTIONS].
Advise patients to inform their physician if they develop a rash after receiving OPTIRAY [see WARNINGS AND PRECAUTIONS].
Advise the patient concerning appropriate hydration to decrease the risk of contrast induced kidney injury [see WARNINGS AND PRECAUTIONS].
If extravasation occurs during injection, advise patients to seek medical care for progression of symptoms [see WARNINGS AND PRECAUTIONS].
Advise parents/caregivers about the risk of developing thyroid dysfunction after OPTIRAY administration. Advise parents/caregivers about when to seek medical care for their child to monitor for thyroid function. [see WARNINGS AND PRECAUTIONS].
